Prostate cancer (PCa) and colorectal cancer (CRC) remain among the most common and deadly cancers in the United States, even though both are highly treatable when detected early. This project examines biological factors that drive late-stage disease and poor outcomes, with attention to oxidative stress, hormone signaling, and disparities in diagnosis. In prostate cancer, the work focuses on how androgen receptor signaling contributes to disease progression, including the transition to castration-resistant prostate cancer, a stage that is far more difficult to treat. Particular interest centers on FKBP51 and FKBP52, proteins that regulate androgen receptor activity and may serve as therapeutic targets. In colorectal cancer, the project addresses the consequences of delayed detection, especially among Hispanic patients who are more likely to be diagnosed at later stages than non-Hispanic White patients. Across both cancers, the goal is to identify new biomarkers for earlier detection and new molecular targets for treatment. By improving understanding of the mechanisms that underlie progression and resistance, the work aims to support more effective strategies for diagnosis and therapy in two cancers where timing and biology strongly shape survival.